Clinical application of next-generation sequencing for the management of desmoid tumors
A case report and literature review
Jeong Mi Lee, MD, Han Gyeol Kim, MD, So Youn Shin, MD, PhD, Seung Hyeun Lee, MD, PhD

Abstract
Rationale: Desmoid tumors are rare myofibroblastic neoplasms characterized by local invasiveness and high rates of recurrence, and sometimes mimic local recurrence of previously resected malignancies. Previous studies have suggested that molecular profiling may be useful for the diagnosis of the tumors and risk stratification. However, the clinical utility of next-generation sequencing (NGS) for the management of desmoid tumors has not been established.

Patient concerns: A 42-year-old man visited our clinic for routine follow-up 1 year after left upper lobe lingular segmentectomy for lung adenocarcinoma.

Diagnoses: Chest computed tomography showed a pleural mass adherent to the thoracotomy site. Positron emission tomography revealed mildly increased metabolism with a maximal standardized uptake value of 2.7 within the tumor, suggesting local recurrence of the previous neoplasm. Exploratory thoracotomy and en bloc resection of the tumor revealed spindle cells in a massive collagenous tissue consistent with a desmoid tumor.

Interventions: NGS was performed to confirm the diagnosis and to identify any genetic alterations that might be relevant to the prognosis of this tumor. The tumor harbored an S45F mutation in CTNNB1, which has been correlated with a high recurrence rate. Therefore, we performed adjuvant radiotherapy on the resection bed at a dose of 56 Gy.

Outcomes: The patients experienced no postoperative or radiotherapy-related complications. Periodic follow-up examinations using computed tomography were performed every 3 months, and no evidence of recurrence of either tumor was observed during the 38 months after the last surgery.

Lessons: To the best of our knowledge, this is the first case reporting the clinical application of NGS and aggressive treatment based on the genotyping results for the management of a desmoid tumor. Our case highlights the need to consider desmoid tumors among the differential diagnoses when a pleural mass is encountered at a previous thoracotomy site. More importantly, molecular profiling using NGS can be useful for the establishment of a treatment strategy for this tumor, although further investigations are required.

Abbreviations: CT = computed tomography, NGS = next-generation sequencing, PET = positron emission tomography, SUVmax = maximal standardized uptake value.

Keywords: β-catenin, case report, CTNNB1, desmoid tumor, lung cancer, next-generation sequencing, thoracotomy
1. Introduction

Desmoid tumor, also known as desmoid-type fibromatosis, is a rare mesenchymal soft tissue tumor arising from myofibroblasts. This tumor is characterized by variable clinical behavior and an unpredictable natural course; most tumors gradually grow over time, some are indolent, and spontaneous regression is not uncommon. Most desmoid tumors (85–90%) develop sporadically and are associated with somatic mutation of the CTNNB1 that encodes β-catenin. Recent genomic studies have suggested that specific CTNNB1 genotypes are associated with the risk of recurrence after treatment and the high sensitivity of next-generation sequencing (NGS) facilitates the detection of these genotypes. However, the utility of NGS results for the management of desmoid tumors has not been established.

Here, we report a case of a desmoid tumor mimicking pleural recurrence of a previously resected lung adenocarcinoma. We adopted an aggressive treatment strategy based on the NGS results and obtained a favorable outcome. We comprehensively reviewed previous reports on desmoid tumors that developed after thoracotomy as well as relevant studies on the clinical significance of genomic profiling of these tumors to highlight the possible utility of NGS for patient care and management.

2. Case report

A 42-year-old man visited our clinic for routine follow-up 1 year after left upper lobe lingular segmentectomy for T1bN0M0 lung adenocarcinoma. He had never smoked and had no medical history. He had no symptoms and physical examination showed no significant findings. Chest computed tomography (CT) showed a newly developed pleural mass on the left hemithorax. The tumor was 34 mm × 25 mm and located in the pleural space (Fig. 1A). Positron emission tomography (PET) revealed mild 18F-fluorodeoxyglucose uptake with a maximal standardized uptake value (SUVmax) of 2.7 within the tumor (Fig. 1B). There was no distant metastasis on PET and brain magnetic resonance imaging. The carcinoembryonic antigen value was 2.38 ng/mL, which was similar to the preoperative value.

Given that pleural recurrence of a lung adenocarcinoma was highly suspected, we decided to perform an exploratory thoracotomy. A well-circumscribed ovoid mass was found in the parietal pleura around the fifth intercostal space, which corresponded to the previous thoracotomy site. En bloc resection of the tumor, ribs, and intercostal muscle was performed, followed by chest wall reconstruction. Histopathology showed fibroblastic proliferation appearing as small bundles of spindle cells in abundant fibrous stroma and the spindle cells were positive for vimentin and β-catenin immunohistochemical staining, which was consistent with a desmoid tumor (Fig. 2). Next, we performed NGS to confirm the diagnosis and to identify any genetic alterations that might be relevant for the prognosis of this tumor. A missense mutation S45F (serine to phenylalanine substitution at codon 45) of CTNNB1 was detected. Previous studies have reported that the presence of CTNNB1 mutations can be a diagnostic marker for desmoid tumors among spindle-cell tumors, and a specific genotype, S45F mutation, is associated with a high recurrence rate compared to other genotypes. Therefore, we were able to confirm the patient’s diagnosis and predict the aggressive behavior of this tumor. We decided to perform adjuvant radiotherapy to prevent local recurrence of the tumor. A total of 56 Gy was delivered to the resection bed in 28 fractions during the daily course. There were no postoperative or radiotherapy-related complications during the treatment.

The patient underwent periodic follow-up examinations, including laboratory tests and CT every 3 months, and is currently alive without recurrence of lung cancer as well as a desmoid tumor 38 months after the last surgery.

3. Discussion

Surgical trauma has been suggested as a risk factor for desmoid tumors, and several cases that develop after previous thoracotomy have been reported. Desmoid tumors following thoracotomy for lung cancer often mimic the local recurrence of the previous malignancy and require differential diagnosis. We reviewed the literature and summarized fifteen previous cases and the current case that reported the development of desmoid tumors...
after thoracotomy in Table 1. The mean age of the patients was 57 years (range, 24–78 years), and cases in males were slightly predominant (56%, 9/16). Ten cases (62.5%) occurred at the site of the previous thoracotomy. Preoperative biopsy was performed in seven cases (43.7%); however, all except one case were non-diagnostic. Prognosis could not be estimated because of the lack of data on recurrence in most of the cases, but the clinical course appeared to be variable. The data suggest that desmoid tumors develop after thoracotomy either at the same or a different site, can occur at any age, and needle biopsy may not be useful for a definitive diagnosis.

As desmoid tumors often mimic the local recurrence of a previous malignancy, PET can be a useful tool for differential diagnosis. Only three cases, including the present case, have described PET data and reported that tumors exhibit increased metabolism (2.7–2.8 of SUVmax). Kasper et al analyzed the PET results of 16 desmoid tumors and demonstrated that SUVmax was variable, ranging from 1.0 to 8.1 with a median of 4.1. These data indicate that PET may not be useful for the discrimination of desmoid tumors from the recurrence of previously resected malignancies.

Studies have shown that dysregulated wound healing is involved in the pathogenesis of desmoid tumor-like fibroblastic lesions. In particular, the sporadic type of desmoid tumor is associated with CTNNB1 mutations, which dysregulate the β-catenin level and induce nuclear accumulation of β-catenin. Recent molecular studies have demonstrated that mutational analysis for CTNNB1 is clinically significant for the diagnosis of desmoid tumors. Le Guelc et al performed genomic sequencing using 260 desmoid tumors and 191 desmoid-like spindle cell lesions. They demonstrated that 88% of the desmoid tumors showed exclusively CTNNB1 mutations, suggesting that detection of these mutations could be useful for discriminating desmoid tumors from other spindle cell tumors. A subsequent study using various molecular profiling methods, including whole-exome sequencing, demonstrated that the genetic alterations in CTNNB1 were almost universal in sporadic desmoid tumors.

Despite complete resection, desmoid tumors have a high rate of recurrence, and the contribution of incomplete resection to local recurrence rate remains debatable. A meta-analysis of 16 retrospective studies revealed that patients with microscopically negative margins at the initial resection were more likely to have a recurrence than those with positive margins. Therefore, it is important to perform careful resection and consider adjuvant therapy in high-risk patients.

Table 1

| Author, year | Sex/age | Tumor diameter (cm) | PET-SUVmax | Previous disease for thoracotomy | Occurrence in thoracotomy site | Biopsy results | Treatment | Recurrence (time to recurrence) |
|--------------|---------|---------------------|------------|---------------------------------|------------------------------|----------------|-----------|----------------------------------|
| Guistra et al, 1979 | M/42 | 9                   | –          | Peptic ulcer (vagotomy)         | Yes                          | ND             | Resection | Yes (5 years)                    |
| Mole et al, 1990 | F/24 | 25                  | –          | Heart disease                   | Yes                          | ND             | Resection | Yes (2 years)                    |
| Shimizu et al, 1999 | M/74 | 7.6                 | Yes        | Lung cancer                     | Non-diagnostic               | Resection No | –         |                                  |
| Haoka, et al, 2002 | F/78 | 8                   | No         | Lung cancer                     | Non-diagnostic               | Resection No | –         |                                  |
| Hashimoto et al, 2002 | M/56 | 3                   | –          | Lung cancer                     | No                           | ND             | Resection | –                                |
| Yasuoka et al, 2003 | F/70 | –                   | –          | Lung cancer                     | ND                           | Resection No | –         |                                  |
| Tsujibushima et al, 2000 | F/62 | 6                   | –          | Lung cancer                     | Non-diagnostic               | Resection –   | –         |                                  |
| Arimura et al, 2008 | M/20s | 2.5                 | Yes        | Metastasectomy                  | Non-diagnostic               | Resection –   | –         |                                  |
| Yoshida et al, 2008 | F/65 | 4.5                 | Yes        | Lung cancer                     | Non-diagnostic               | Resection –   | –         |                                  |
| Arimura et al, 2010 | M/80s | 3.3                | Yes        | Lung cancer                     | Non-diagnostic               | Resection No | –         |                                  |
| Miwatani et al, 2017 | M/75 | 8                   | Yes        | Lung cancer                     | Non-diagnostic               | Resection No | –         |                                  |
| Endo et al, 2010 | F/69 | 7                   | –          | Lung cancer                     | ND                           | Resection –   | –         |                                  |
| Zehari-Kassar et al, 2011 | M/39 | 11.5                | Yes        | Hydatid cyst                    | ND                           | Resection –   | –         |                                  |
| Matsukuma et al, 2012 | M/76 | 5.2                 | Yes        | Desmoid tumor                   | Resection No                 | –              | –         |                                  |
| Mori et al, 2014 | F/62 | 7.4                 | Yes        | Lung cancer                     | Non-diagnostic               | Resection No | –         |                                  |
| The present case, 2020 | M/42 | 3.4                 | Yes        | Lung cancer                     | ND                           | Resection plus | –         | –                                |

– = not available, F = female, M = male, ND = not done, PET-SUVmax = positron emission tomography-maximal standardized uptake value.
cally positive resection margins had a significantly higher recurrence risk. In contrast, another study reported high recurrence rates (up to 38%) even in tumors that were aggressively treated with resection with widely negative margins. Although the anatomic site of disease, size, gender, and age have been suggested as factors associated with the recurrence rate, the significance of each variable has been inconsistent across studies. Therefore, finding predictive factors for recurrence is essential for the proper management of desmoid tumors.

Interestingly, molecular subtypes of CTNNB1 or specific gene expression signatures are emerging as biomarkers for recurrence risk. We have summarized previous studies on the putative molecular biomarkers for desmoid tumors in Table 2. An early study showed that overexpression of β-catenin and p53 was related to a high local recurrence rate. Other studies have suggested that the presence of CTNNB1 mutations, midkine expression, or certain molecular signatures are associated with local recurrence. Of note, several studies have demonstrated that a specific mutation of CTNNB1, S45F, is a reliable molecular predictor of local recurrence. Lazar et al first demonstrated that S45F was associated with high recurrence rate (23% of 5-year recurrence-free survival in S45F-mutant tumors compared to 57% in S41A-mutant and 65% in wild-type tumors). Colombo et al and van Broekhoven et al confirmed the predictive value of the genotype in separate studies, although one study found no association between the genetic alterations and recurrence rate. A subsequent report indicated that NGS has high sensitivity (92.3%) and specificity (100%) for the detection of the CTNNB1 mutations in desmoid tumor-like spindle cell lesions, suggesting that the assay may be clinically useful for the detecting mutations. Given that we detected S45F mutation following NGS, we opted to treat the patient using adjuvant radiotherapy even after radical resection. To the best of our knowledge, this is the first report of clinical decision-making and aggressive treatment based on NGS genotyping for the management of desmoid tumors. Although repeated resection, radiotherapy, and systemic treatment are used either alone or in combination, the optimal management of patients with desmoid tumors is yet to be determined due to its rarity and unpredictable behavior. Moreover, the utility of post-operative radiotherapy remains inconclusive. The National Comprehensive Cancer Network guideline suggests that postoperative radiotherapy should be considered after R2 resection or in the setting of disease progression or recurrence, with or without surgery. The role of adjuvant radiotherapy and optimal treatment strategy, especially for tumors that are predicted to be aggressive based on genotyping, should be the subject of future studies.

4. Conclusion

Diagnosis of desmoid tumors is usually incidental and challenging, particularly in cases with no clinical symptoms. Although tumors rarely metastasize distantly, they are often locally invasive. Occasionally, desmoid tumors develop at the site of previous surgical resection mimicking local recurrence of a previous malignancy. Here, we describe a rare case of a desmoid tumor arising at the antecedent thoracotomy site. As the molecular profiling demonstrated that the tumor harbored the CTNNB1 S45F mutation which is associated with an aggressive phenotype, we performed adjuvant radiotherapy even after radical resection. Our case highlights the potential role of NGS as a supplementary tool for diagnosis and risk stratification, although other factors influencing clinical outcome and the optimal therapeutic strategy remain to be established. In addition, desmoid tumors should be included in differential diagnoses when clinicians encounter a chest wall mass in a patient who has previously undergone thoracotomy.

Acknowledgments

The authors thank the patient and his family for permission to publish this case report.

Author contributions

Conceptualization: Seung Hyeun Lee.
Data curation: So Youn Shin, Seung Hyeun Lee.
Formal analysis: Jeong Mi Lee, Han Gyeol Kim, So Youn Shin, Seung Hyeun Lee.
Methodology: Han Gyeol Kim, Seung Hyeun Lee.
Project administration: Seung Hyeun Lee.
Supervision: So Youn Shin, Seung Hyeun Lee.
Validation: Jeong Mi Lee, Seung Hyeun Lee.
Visualization: Jeong Mi Lee, Seung Hyeun Lee.
Writing – original draft: Jeong Mi Lee, Seung Hyeun Lee.
Writing – review & editing: Jeong Mi Lee, Seung Hyeun Lee.
References

[1] Penel N, Chibon F, Salas S. Adult desmoid tumors: biology, management and ongoing trials. Curr Opin Oncol 2017;29:268–74.

[2] Fiore M, Rimarex F, Mariani L, et al. Desmoid-type fibromatoses: a front-line comparative approach to select patients for surgical treatment. Ann Surg Oncol 2009;16:2587–93.

[3] Salas S, Dufresne A, Bui B, et al. Prognostic factors influencing progression-free survival derived from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol 2009;27:3553–8.

[4] Bonvalot S, Ternes N, Fiore M, et al. Spontaneous regression of primary abdominal wall desmoid tumors: more common than previously thought. Ann Surg Oncol 2013;20:4096–102.

[5] Burtenshaw SM, Cannell AJ, McAlister ED, et al. Toward observation as first-line management in abdominal desmoid tumors. Ann Surg Oncol 2016;23:2212–9.

[6] Lazar AJ, Tuvin D, Hajihashi S, et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Ann J Pathol 2008;173:1518–27.

[7] Domont J, Salas S, Lacroix L, et al. High frequency of beta-catenin homozygous mutations in extra-abdominal fibromatoses: a potential molecular tool for disease management. Br J Cancer 2010;102:1032–6.

[8] Colombo C, Miceli R, Lazar AJ, et al. CTNNB1 43F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study. Cancer 2013;119:6366–702.

[9] Salas S, Brulard C, Terrier P, et al. Gene expression profiling of desmoid tumors by cDNA microarrays and correlation with progression-free survival. Clin Cancer Res 2015;21:4194–200.

[10] Arkin SJ, Presneau N, Kalmuth D, et al. Next-generation sequencing is highly sensitive for the detection of beta-catenin mutations in desmoid-type fibromatoses. Virchows Arch 2013;467:203–10.

[11] Le Guellc S, Soubeyran I, Rochaix P, et al. CTNNB1 mutation analysis and ongoing trials. Curr Opin Oncol 2017;29:268–74.

[12] Giustra PE, White HO, Killoran PJ. Intrathoracic desmoid at previous lobectomy for lung cancer. J Jpn Assoc Chest Surg Respir 2002;40:1891–4.

[13] Mole MT, Goldstraw P, Sheppard MN. Desmoid tumour in thoracotomy scar one year after VATS for lung cancer. Proceedings of 158th Kanto and Koshin-Etsu branch meeting of the Japanese association for thoracic surgery, 28; 2012 (in Japanese).

[14] Shimizu J, Kawaura Y, Tatsuzawa Y, et al. Desmoid tumor of the chest wall following chest surgery: report of a case. Surg Today 1999;29:945–7.

[15] Hanaoka S, Kojima F, Nakajima D. A case of Desmoid tumor following lung cancer surgery. Ann Jap Respir Soc 2002;40:x213.

[16] Hashimoto T, Kawakami M, Tokitsu K, et al. A case of Desmoid tumor in late follow up period for lung cancer surgery. J Jpn Assoc Chest Surg Respir 2002;40:419–21. (in Japanese).

[17] Yasaoka T, Bino Y, Murata M, et al. A case of desmoid tumor of the chest wall following lung cancer surgery. Jpn Assoc Chest Surg Respir 2012;41:119–21. (in Japanese).

[18] Tsushoike T, Nishio H, Kanetsuki K, et al. A case of desmoid tumor of the chest wall after right middle lobectomy for lung cancer. J Jpn Assoc Chest Surg Respir 2005;66:1891–4. (in Japanese).

[19] Arimura T, Nishimura H, Hamanaka K, et al. A case of desmoid tumor of the chest wall after the resection of pulmonary tumor. J Jpn Assoc Chest Surg Respir 2010;40:419–22. (in Japanese).

[20] Yoshida T, Kumimura T, Sato M, et al. A case of the chest wall tumor arising from the thoracotomy site for lung cancer. Proc Jpn Soc Pathol 2008;97:377–9. (in Japanese).

[21] Arimura T, Nishimura H, Yamada K, et al. Two case of desmoid tumor of the chest wall after the resection of pulmonary tumor. J Jpn Assoc Chest Surg Respir 2010;40:419–22. (in Japanese).

[22] Mizutani E, Morita R, Kitamura S, et al. A case of desmoid tumor of the chest wall arising from thoracotomy scar for lung cancer. J Jpn Assoc Chest Surg Respir 2010;40:419–21. (in Japanese).

[23] Endo T, Fukui T, Nakano T, et al. A case of a giant desmoid tumor of the chest wall showing rapid tumor growth in follow up period for lung cancer surgery. J Jpn Assoc Lung Cancer 2010;50:85–8. (in Japanese).

[24] Zehani-Kassar A, Ayadi-Kaddour A, Marghli A, et al. Desmoid-type chest wall fibromatosis. A six cases series. Orthop Traumatol Surg Res 2011;97:102–7.

[25] Matsuokuma H, Suzuki H, Nakahara R et al. A case of a desmoid tumor of the chest wall arising from the VATS scar one year after VATS for lung cancer. Proceedings of 158th Kanto and Koshin-Etsu branch meeting of the Japanese association for thoracic surgery, 28; 2012 (in Japanese).

[26] Mori T, Yamada T, Obha Y, et al. A case of desmoid-type fibromatosis arising after thoracotomy for lung cancer with a review of the English and Japanese literature. Ann Thorac Cardiovasc Surg 2014;20:456–9.

[27] Kasper B, Dimitrakopoulos-Strauss A, Strauss LG, et al. Positron emission tomography in patients with aggressive fibromatoses/desmoid tumours undergoing therapy with imatinib. Eur J Nucl Med Mol Imaging 2010;37:1876–82.

[28] De Wever I, Dal Cin P, Fletcher CD, et al. Cytogenetic, clinical, and morphologic correlations in 78 cases of fibromatoses: a report from the CHAMP Study Group. Chromosomes And Morphology. Mod Pathol 2000;13:1080–5.

[29] Escober C, Munker R, Thomas JO, et al. Update on desmoid tumors. Ann Oncol 2012;23:562–9.

[30] Giarola M, Wells D, Mondini P, et al. Mutations of adenomatous polyposis coli (APC) gene are uncommon in sporadic desmoid tumours. Br J Cancer 1998;78:582–7.

[31] Crago AM, Chmielecki J, Rosenberg M, et al. Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatoses by whole-exome sequencing and genomic analysis. Genes Chromosomes Cancer 2015;54:606–15.

[32] Janssen ML, van Broekhoven DL, Cates JM, et al. Meta-analysis of the influence of surgical margin and adjuvant radiotherapy on local recurrence after resection of sporadic desmoid-type fibromatosis. Br J Surg 2017;104:347–57.

[33] Mullen JT, Delaney TF, Kobayashi WK, et al. Desmoid tumor: analysis of prognostic factors and outcomes in a surgical series. Ann Surg Oncol 2012;19:4028–35.

[34] Mankin HJ, Hornick FJ, Springfield DS. Extra-abdominal desmoid tumors: a report of 234 cases. J Surg Oncol 2010;102:380–4.

[35] Huang K, Fu H, Shi YQ, et al. Prognostic factors for extra-abdominal and abdominal wall desmoids: a 20-year experience at a single institution. J Surg Oncol 2009;100:563–9.

[36] Gehert C, Hardes J, Kersting C, et al. Expression of beta-catenin and p53 are prognostic factors in deep aggressive fibromatoses. Histopathology 2007;50:491–7.

[37] Colombo C, Creighton CJ, Ghadimi MP, et al. Increased midkine expression correlates with desmoid tumour recurrence: a potential biomarker and therapeutic target. J Pathol 2011;225:574–82.

[38] van Broekhoven DL, Verhoef C, Grunhagen DJ, et al. Prognostic value of the beta-catenin gene mutation in primary sporadic aggressive fibromatoses. Ann Surg Oncol 2011;18:1043–9.

[39] Mullen JT, DeLaney TF, Rosenberg AE, et al. beta-Catenin mutation status and outcomes in sporadic desmoid tumors. Oncologist 2013;18:1043–9.

[40] National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls [access date August 7, 2020].